According to a new report, published by KBV research, The Global Rabies Vaccine Market size is expected to reach $1.6 billion by 2030, rising at a market growth of 4.5% CAGR during the forecast period.
One of the primary uses of rabies vaccines is post-exposure prophylaxis for individuals who have been bitten or scratched by an animal suspected of carrying the rabies virus. Prompt administration of the rabies vaccine and rabies immune globulin (RIG), if indicated, can prevent the onset of clinical rabies in exposed individuals. This application prevents the virus’s progression after exposure and has effectively saved lives.
The Post-exposure Prophylaxis segment is generating the highest revenue in the Global Rabies Vaccine Market by Prophylaxis Type in 2022; thereby, achieving a market value of $995.7 Million by 2030. The rising incidence of animal bites, particularly in regions where rabies is endemic, has driven the demand for post-exposure prophylaxis. As the awareness of the risk associated with animal bites increases, individuals are more likely to seek medical attention and receive timely rabies vaccination.
The Hospitals segment is registering a CAGR of 4.1 % during the forecast period. Hospitals are key institutions responsible for providing post-exposure prophylaxis (PEP) to individuals potentially exposed to rabies. Administering rabies vaccines and, if necessary, rabies immune globulin (RIG) in hospital settings ensures prompt and appropriate medical care for those at risk. Individuals seeking medical attention after potential rabies exposure often visit hospital emergency departments or urgent care centers.
The Human segment led the Global Rabies Vaccine Market by Application in 2022; thereby, achieving a market value of $1.1 Billion by 2030. The high incidence of human rabies cases, especially in regions where rabies is endemic, underscores the urgent need for effective vaccination programs. The human segment is a primary focus in rabies prevention efforts due to the direct impact of the disease on human health. Promoting pre-exposure prophylaxis (PrEP) in high-risk populations, such as healthcare workers, veterinarians, and travelers to rabies-endemic areas, emphasizes the importance of proactive measures to protect individuals from potential rabies exposure.
The Chick Embryo Cells Rabies Vaccine segment is growing at a CAGR of 3.9 % during the forecast period. Chick embryo cell rabies vaccines eliminate the need for nervous tissue, addressing safety concerns associated with traditional nerve tissue-derived vaccines. Chick embryo cell cultures provide a consistent and controlled environment for vaccine production. This consistency ensures uniform vaccine quality, reducing variability between batches. The standardized manufacturing process contributes to the reliability and efficacy of chick embryo cell rabies vaccines.
Full Report: https://www.kbvresearch.com/rabies-vaccine-market/
The North America region dominated the Global Rabies Vaccine Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $543.1 Million by 2030. The Europe region is anticipated to grow at a CAGR of 4.1% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 5.1% during (2023 - 2030).
By Prophylaxis Type
By End User
By Application
By Product Type
Unique Offerings 
